* agilon health inc AGL.N AGL is expected to show a rise
in
quarterly revenue when it reports results on March 1.
* The Austin Texas-based company is expected to report a
43.5% increase in revenue to $664.358 million from $462.89
million a year ago, according to the mean estimate from 14
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for agilon health inc
is for
a loss of 9 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for agilon
health inc
is $26.5, above its last closing price of $21.16.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.06 -0.05 -0.07 Missed -40
Jun. 30 2022 -0.02 -0.02 -0.05 Missed -177.8
Mar. 31 2022 0.00 0.00 0.00 Met -100
Dec. 31 2021 -0.14 -0.11 -0.14 Missed -27.3
Sep. -0.10 -0.10 -0.09 Beat 6.9
30 2021
Jun. 30 2021 -0.06 -0.05 -0.79 Missed -1,336
.4
Mar. 31 2021 -0.03 -0.03 -0.05 Missed -66.7
This summary was machine generated February 28 at 01:45 GMT.
All figures in US dollars unless otherwise stated